. 2017 Feb 17;12(2):e0172206. doi: 10.1371/journal.pone.0172206

Table 1. Cross-study frequency of pre- and on-treatment integrase genotypes with or without T97A mutation.

Study Drug(s)^a	Study No.	PT POP^b	Pre-Treatment			On-Treatment^c
Study Drug(s)^a	Study No.	PT POP^b	INSTI Treatment Arm	Integrase Genotype	T97A; Pre-Existing (Enrolled on INSTI)	Primary INSTI RAMs	T97A Alone^d (Emergent)
TDF	01-934/ 99–903	TN	0	200	1 (0)	-	-
TDF	99–907	TE	0	110	0	-	-
EVG (125 mg)/r+OBR	183–0105	TE	73	277	0	37	0
EVG (85/150 mg)/r+BR	183-0130/0145/ 0152	TE	375	164	3 (3)	30	6 (5)
RAL (400 mg)+BR	183–0145	TE	351	152	0	26	2 (2)
EVG (150 mg)/ COBI/FTC/TDF	236-0102/0103/ 0104/0118/ 0128	TN	1071	475	17 (14)	15	1 (1)
EVG (150 mg)/ COBI/FTC/TAF or EVG (150 mg)/ COBI/FTC/TDF	292-0102/0104/ 0106/ 0111	TN	2011	1989	26 (1)	14	0
Total:			3881	3367	47 (18)	122	9 (8)

BR, background regimen; OBR, optimized background regimen; PT POP, patient population; TE, treatment-experienced; TN, treatment-naive; INSTI, integrase strand transfer inhibitor; TDF, tenofovir disoproxil fumarate; EVG, elvitegravir; RAL, raltegravir

^a OBR included ≥2 NRTIs ± ENF with documented ≥1 PI mutation(s). BR included active PI + active/inactive 2nd agent (NRTI, ETR, MVC, ENF) with EVG 85 mg once a day (ATV/r or LPV/r), EVG 125 mg once a day (DRV/r, FPV/r, or TPV/r), or RAL 400 mg twice a day.

^b Patients were either highly antiretroviral treatment-experienced (INSTI-naive) with 1–2 class resistance or antiretroviral treatment-naive (INSTI-naive).

^c Only patients that received clinically approved EVG 150 mg once a day, bioequivalent EVG 85/125 mg once a day, or RAL 400 mg twice a day were included in on-treatment analysis of integrase genotypes.

^d Alone, defined as in the absence of primary INSTI RAM(s)